Specifically, SARS-CoV-2–specific antibodies able to bind to low affinity FcRs (FcγR2A, FcγR2B, FcγR3A, and FcγR3B) were generated at lower levels in nonsurvivors compared with COVID-19 survivors (fig. This evidence concerns the gene FCGR3B and COVID-19.